A new tool to study ribavirin-induced haemolysis

Antiviral Therapy

Volumn 17, Issue 7, 2012, Pages 1311-1317

  Brochot, Etienne ^a,b   François, Catherine ^a,b   Castelain, Sandrine ^a,b   Helle, François ^b   Van Nhien, Albert Nguyen ^b   Duchaussoy, Isabelle ^a   Capron, Dominique ^a   Nguyen Khac, Eric ^a   Duverlie, Gilles ^a,b  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DIPYRIDAMOLE; GLUTATHIONE; HEMOGLOBIN; INOSINE TRIPHOSPHATE; PEGINTERFERON ALPHA2B; RIBAVIRIN; TARIBAVIRIN;

ADULT; ARTICLE; CELL SUSPENSION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; GENETIC POLYMORPHISM; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; SIDE EFFECT; SPECTROPHOTOMETRY;

ADENOSINE TRIPHOSPHATE; ADULT; ANEMIA, HEMOLYTIC; DIPYRIDAMOLE; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; ERYTHROCYTES; GLUTATHIONE; HEMATOLOGIC TESTS; HEMOLYSIS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INHIBITORY CONCENTRATION 50; INTERFERON-ALPHA; POLIOVIRUS; POLYETHYLENE GLYCOLS; PRODRUGS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL;

EID: 84870517829     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2308     Document Type: Article

References (24)

1. Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107:812-817.
2. Jacobson IM, Brown RS, Jr., McCone J, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 2007; 46:982-990.
3. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
4. Homma M, Matsuzaki Y, Inoue Y, et al. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin Gastroenterol Hepatol 2004; 2:337-339.
5. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31:997-1004.
6. Brochot E, Castelain S, Duverlie G, Capron D, Nguyen-Khac E, Francois C. Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy. Antivir Ther 2010; 15:687-695.
7. Hung CH, Lee CM, Lu SN, et al. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. Liver Int 2006; 26:1079-1086.
8. Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464:405-408.
9. Asselah T, Pasmant E, Lyoumi S. Unraveling the genetic predisposition of ribavirin-induced anaemia. J Hepatol 2010; 53:971-973.
10. Grattagliano I, Russmann S, Palmieri VO, Portincasa P, Palasciano G, Lauterburg BH. Glutathione peroxidase, thioredoxin, and membrane protein changes in erythrocytes predict ribavirin-induced anemia. Clin Pharmacol Ther 2005; 78:422-432.
11. Kini GD, Robins RK, Avery TL. Synthesis and antitumor activity of ribavirin imidates. A new facile synthesis of ribavirin amidine (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride). J Med Chem 1989; 32:1447-1449.
12. Maeda T, Sumi S, Ueta A, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol Genet Metab 2005; 85:271-279.
13. Inoue Y, Homma M, Matsuzaki Y, et al. Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy. Hepatol Res 2006; 34:23-27.
14. Jarvis SM, Thorn JA, Glue P. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br J Pharmacol 1998; 123:1587-1592.
15. Marcellin P, Gish RG, Gitlin N, et al. Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients. J Hepatol 2010; 52:32-38.
16. Poordad F, Lawitz E, Shiffman ML, et al. Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. Hepatology 2010; 52:1208-1215.
17. Grattagliano I, Russmann S, Palmieri VO, et al. Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C. Hepatology 2004; 39:1248-1255.
18. Endres CJ, Moss AM, Govindarajan R, Choi DS, Unadkat JD. The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1-/- mice. J Pharmacol Exp Ther 2009; 331:287-296.
19. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999; 19 Suppl 1:17-24.
20. Alavian SM, Tabatabaei SV. Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis. J Viral Hepat 2010; 17:236-244.
21. Loustaud-Ratti V, Alain S, Rousseau A, et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 2008; 47:1453-1461.
22. Arase Y, Ikeda K, Tsubota A, et al. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology 2005; 48:138-144.
23. Thompson AJ, Fellay J, Patel K, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010; 139:1181-1189.
24. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet 2010; 376:705-716.